Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English


Warning: getimagesize(images/pics/539258-automated-buffy-coat-isolation-on.jpg) [function.getimagesize]: failed to open stream: No such file or directory in /var/www/prinsidecom/htdocs/inc/release_details.php on line 330
Science

Automated buffy coat isolation on Tecan’s Freedom EVO®


Print article Print article

The IBBL team with the Freedom EVO
The IBBL team with the Freedom EVO
2013-01-23 13:05:19 - Tecan and IBBL (Integrated BioBank of Luxembourg) have successfully co-developed an automated platform for buffy coat extraction based on a Freedom EVO® 200 workstation.

Tecan and IBBL (Integrated BioBank of Luxembourg) have successfully co-developed an automated platform for buffy coat extraction based on a Freedom EVO® 200 workstation, relieving scientific staff from performing this time-consuming task, and significantly increasing the yield of DNA.



The process of manually isolating the buffy coat from whole blood is traditionally slow, tedious and very dependent on the skill and dexterity of the technician separating the layers. This lengthy and variable element of sampling has been eliminated by automating the procedure on a Freedom EVO 200 platform, optimized to maximize the yield and quality of the buffy coat and minimize the risk of cross-­contamination.



Fay Betsou, Chief of Biospecimen Science at IBBL, explained: “The Freedom EVO’s Liquid Handling

(LiHa) Arm pipettes the buffy coat layer with very precise orientation and speed, standardizing the process and eliminating technician-to-technician variation. This gives a purer buffy coat product, with less contamination from red blood cells and hemoglobin and a similar distribution of white blood cells. The results are amazing; the DNA yield is 10­-15 % higher using the automated process, and the Freedom EVO system can process 24 samples in just 16 minutes. We are very satisfied with the system, and are looking forward to working with Tecan on another biospecimen research project in the near future.”



To find out more about Tecan’s biobanking solutions, visit www.tecan.com/biobanking



For more information please contact

Tecan Trading AG

Cornelia Kegele / Antonietta Allocca

Seestrasse 103, CH-8708 Männedorf

Tel +41 (0)44 922 81 11, Fax +41 (0)44 922 81 12

info@tecan.com www.tecan.com



About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).







For more information about IBBL, please visit: www.ibbl.lu.

Press Contact for IBBL

Arnaud d’Agostini

Communications Manager, IBBL

6 rue Nicolas Ernest Barblé

L-1210 Luxembourg

Tel: +352 44 24 64 - 24, Fax: +352 44 24 64 - 64

E-mail: arnaud.dagostini@ibbl.lu

Web: www.ibbl.lu



About IBBL

IBBL (Integrated BioBank of Luxembourg) is an independent, not-for-profit Luxembourg-based biobank dedicated to improving health outcomes for patients by supporting high standards of medical research. IBBL serves as an international centre of excellence in biobanking, and helps to accelerate the introduction of personalised healthcare in Luxembourg. IBBL collects, stores, and analyses biological samples and associated data, which are available to research organisations investigating human diseases. IBBL has built an integrated infrastructure offering biospecimens, data, technologies and biospecimen research to support a successful biomedical research industry in Luxembourg and facilitate rapid translation of discoveries into improved care. IBBL also provides administrative support to the Luxembourg Personalized Medicine Consortium (PMC). With the help of the people of Luxembourg, IBBL catalyses partnerships and supports research that translates today’s discoveries into tomorrow’s healthcare solutions.


Author:
Sophie Woodward
e-mail
Web: www.kdm-communications.com
Phone: 01480405333

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser